GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OBI Pharma Inc (ROCO:4174) » Definitions » Margin of Safety % (DCF Earnings Based)

OBI Pharma (ROCO:4174) Margin of Safety % (DCF Earnings Based) : N/A (As of May. 07, 2025)


View and export this data going back to 2015. Start your Free Trial

What is OBI Pharma Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

OBI Pharma's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

Competitive Comparison of OBI Pharma's Margin of Safety % (DCF Earnings Based)

For the Biotechnology subindustry, OBI Pharma's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OBI Pharma's Margin of Safety % (DCF Earnings Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OBI Pharma's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where OBI Pharma's Margin of Safety % (DCF Earnings Based) falls into.


;
;

OBI Pharma Margin of Safety % (DCF Earnings Based) Related Terms

Thank you for viewing the detailed overview of OBI Pharma's Margin of Safety % (DCF Earnings Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

OBI Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OBI Pharma Inc (ROCO:4174) » Definitions » Margin of Safety % (DCF Earnings Based)
Comparable Companies
TPE:6541 ROCO:6696 ROCO:6976 ROCO:6617 ROCO:6586 TPE:4142 ROCO:7759 ROCO:4162 TPE:6949 ROCO:4157 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
No. 508, Section. 7, Zhongxiao East Road, 6th Floor, Nangang District, Taipei, TWN, 115011
Website
https://www.obipharma.com
OBI Pharma Inc is a clinical-stage oncology company. It focuses on research and development for cancer therapies and aims to develop ground-breaking drugs. The core value lies in its passion to develop and deliver a portfolio of antibody-drug conjugates (ADCs) drugs for patients, in addition to its Globo H active immunotherapy. Its portfolio includes a spectrum of cancer targets, such as TROP2, Nectin-4, HER2, and other potential targets. These ADCs are built based on two distinct ADC technology platforms, with different characteristics. It offers a plug-and-play advantage through a specialized site-specific conjugation using a proprietary enzyme. Its segments are the anti-cancer new drug; bispecific monoclonal antibody new drug; botulinum toxin new drug; and CDMO segment.

OBI Pharma Headlines

No Headlines